

Edgar Filing: Edge Therapeutics, Inc. - Form 8-K

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: Edge Therapeutics, Inc. - Form 8-K

Item 2.02 Results of Operations and Financial Condition

On November 1, 2016, Edge Therapeutics, Inc. issued a press release announcing its financial results for the three months ended September 30, 2016. A copy of that press release and the financial schedules attached thereto is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The information in this Item 2.02, as well as Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits

Exhibit Number	Description
-------------------	-------------

99.1	Press release dated November 1, 2016 announcing financial results for the three months ended September 30, 2016.
------	--

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 1, 2016 Edge Therapeutics, Inc.

By: /s/ Andrew J. Einhorn
Name: Andrew J. Einhorn
Title: Chief Financial Officer

Exhibit Index

Exhibit Number	Description
<u>99.1</u>	Press release dated November 1, 2016 announcing financial results for the three months ended September 30, 2016.
